Last reviewed · How we verify
Optimized medical BPH treatment
This drug targets the alpha-1 adrenergic receptor to relax smooth muscle in the prostate.
This drug targets the alpha-1 adrenergic receptor to relax smooth muscle in the prostate. Used for Benign prostatic hyperplasia (BPH).
At a glance
| Generic name | Optimized medical BPH treatment |
|---|---|
| Sponsor | University Hospital, Bordeaux |
| Drug class | Alpha-1 adrenergic receptor antagonist |
| Target | Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 3 |
Mechanism of action
By blocking the alpha-1 adrenergic receptor, the drug reduces the size of the prostate and alleviates symptoms of benign prostatic hyperplasia (BPH). This is achieved through a reduction in smooth muscle tone in the prostate, leading to improved urine flow and reduced symptoms.
Approved indications
- Benign prostatic hyperplasia (BPH)
Common side effects
- Dizziness
- Headache
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Optimized medical BPH treatment CI brief — competitive landscape report
- Optimized medical BPH treatment updates RSS · CI watch RSS
- University Hospital, Bordeaux portfolio CI